Should I buy or sell Antibe Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATE, but not buy additional shares or sell existing shares. View ATE analyst ratings or view top-rated stocks .

How have ATE shares performed in 2024?

Antibe Therapeutics' stock was trading at C$0.93 at the start of the year. Since then, ATE stock has decreased by 68.3% and is now trading at C$0.30. View the best growth stocks for 2024 here .

When is Antibe Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ATE earnings forecast .

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (TSE:ATE) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.04.

Is Antibe Therapeutics a good dividend stock?

Antibe Therapeutics (TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.

How do I buy shares of Antibe Therapeutics?

Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:ATE

Antibe Therapeutics (ATE) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ATE Stock Alerts

C$0.30

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: C$0.30
▼
C$0.30
50-Day Range: C$0.17
▼
C$1.03
52-Week Range: C$0.15
▼
C$1.23

Volume: N/A
Average Volume: 135,475 shs
Market Capitalization: C$15.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines Insider Trades

Get Antibe Therapeutics alerts:

Ad Porter & Company

New York goes dark, then America.

Artificial intelligence is about to trigger a shocking new crisis in New York. Experts warn it could be “the next 9/11” and while New York will be ground zero for this looming catastrophe, it will not be the only state impacted. This crisis could affect 233 million Americans starting at any moment from now.

Click here for the full story.

About Antibe Therapeutics Stock (TSE:ATE)

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

ATE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATE Stock News Headlines

April 9, 2024 | finance.yahoo.com

Canadian Investment Regulatory Organization Trading Halt - ATE

March 4, 2024 | finance.yahoo.com

Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma

April 20, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

February 1, 2024 | finance.yahoo.com

Antibe Extends Early Warrant Exercise Incentive Program

December 31, 2023 | morningstar.com

Antibe Therapeutics Inc ATE

December 29, 2023 | finance.yahoo.com

Antibe Announces Early Warrant Exercise Incentive Program

November 13, 2023 | finance.yahoo.com

Antibe Reports Q2 2024 Interim Financial and Operating Results

November 8, 2023 | theglobeandmail.com

Antibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)

April 20, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

November 6, 2023 | baystreet.ca

Hercules at 52-Week High on Barrick Hookup

November 1, 2023 | baystreet.ca

Antibe at 52-Week High on News

November 1, 2023 | finance.yahoo.com

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

October 18, 2023 | benzinga.com

Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation

September 28, 2023 | ca.finance.yahoo.com

Stocks in play: Antibe Therapeutics Inc.

September 28, 2023 | finance.yahoo.com

Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

September 6, 2023 | investing.com

Antibe Therapeutics Inc. (ATE)

August 21, 2023 | finance.yahoo.com

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

August 21, 2023 | finance.yahoo.com

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

August 17, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)

June 30, 2023 | finance.yahoo.com

Antibe Therapeutics Inc.'s (TSE:ATE) Path To Profitability

June 23, 2023 | baystreet.ca

Last Week of June Looks Eventful

June 16, 2023 | travel.usnews.com

Best Times To Visit Antibes

June 13, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc up on Monday (ATE)

June 3, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc down on Friday (ATE)

May 19, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc up on Thursday (ATE)

April 28, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)

April 25, 2023 | finance.yahoo.com

Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

See More Headlines

Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/20/2024
Next Earnings (Estimated): 7/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:ATE
CUSIP: N/A
CIK: N/A
Web: www.antibethera.com
Phone: +1-905-5705103
Fax: N/A
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($0.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 0.56
P/E Growth: N/A
Net Income: C$-18,240,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -52.72%
Return on Assets: -19.13%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 10.06
Quick Ratio: 9.58

Sales & Book Value

Annual Sales: C$9.71 million
Price / Sales: 1.60
Cash Flow: C$0.48 per share
Price / Cash Flow: 0.61
Book Value: C$0.49 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 52,670,000
Free Float: N/A
Market Cap: C$15.54 million
Optionable: Not Optionable
Beta: 0.12

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Daniel Marcel Legault J.D. (Age 66)
L.L.B., President, CEO, Secretary & Director
Comp: $744.67k
Mr. Alain Wilson M.B.A.
MBA, Chief Financial Officer
Mr. Scott Curtis C.F.A.
M.Eng, Chief Operating Officer
Dr. David James Vaughan Ph.D. (Age 74)
Chief Development Officer
Comp: $406.58k
Dr. Joseph Stauffer D.O. (Age 58)
M.B.A., Chief Medical Officer
Comp: $1.11M
Dr. Ana Stegic
Executive Director of Clinical Operations
Ms. Christina Cameron B.B.A.
Vice President of Investor Relations
Mr. Philip Stern
Vice President of Communications

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATE, but not buy additional shares or sell existing shares.
View ATE analyst ratings or view top-rated stocks.
How have ATE shares performed in 2024?: Antibe Therapeutics' stock was trading at C$0.93 at the start of the year. Since then, ATE stock has decreased by 68.3% and is now trading at C$0.30.
View the best growth stocks for 2024 here.
When is Antibe Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024.
View our ATE earnings forecast.
How were Antibe Therapeutics' earnings last quarter?: Antibe Therapeutics Inc. (TSE:ATE) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.04.

Is Antibe Therapeutics a good dividend stock?: Antibe Therapeutics (TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.
How do I buy shares of Antibe Therapeutics?: Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:ATE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial